Coronavirus

AZD1222 US Phase III Trial

The AstraZeneca’s AZD1222 US Phase III Trial demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease…







Ivermectin Against COVID-19?

The US Food and Drug Administration (FDA) recently writes an article about a growing interest in a drug called ivermectin to treat humans with COVID-19….



Lilly’s Bamlanivimab and Etesevimab

On March 10, Eli Lilly and Company announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and…